Intrahepatic cholangiocarcinoma (ICC) is exceptionally rare during pregnancy and requires balancing maternal oncologic evaluation with fetal safety. This case report describes non-contrast magnetic resonance imaging (MRI) and magnetic resonance cholangiopancreatography (MRCP) findings in a woman at 23 weeks’ gestation who presented with abdominal pain and jaundice and was diagnosed with moderately differentiated ICC. Abdominal MRI and MRCP showed an intrahepatic lesion measuring 9 × 9.4 × 8.3 cm, predominantly located in the hepatic hilum. The T2-weighted coronal MRI sequence showed a lobulated, heterogeneously hyperintense intrahepatic tumor. Axial diffusion-weighted imaging (DWI) showed predominantly peripheral diffusion restriction (target-like appearance) with an apparent diffusion coefficient (ADC) of 0.7 × 10-3 mm2/s. The T1-weighted MRI sequence showed a hypointense lesion. The in-phase and out-of-phase sequences revealed central areas of fatty signal. On axial T2-weighted fat-saturation (FS) MRI, the tumor caused subtle liver capsular retraction and obstruction, with dilatation of the left intrahepatic biliary duct to 15.2 mm, corroborated on MRCP. Percutaneous biopsy and histopathologic examination showed moderately differentiated ICC with positive CK7 immunostaining. After biliary drainage, jaundice improved, and the decision was made to continue the pregnancy. This case report highlights the value of non-contrast MRI and MRCP in evaluating intrahepatic lesions during pregnancy, emphasizing their diagnostic utility in this rare clinical context.
B-cell lymphomas are a group of heterogeneic diseases. During B-cell development, the germinal center (GC) reaction is a complex process, in which transcripcional programs have an epigenetic regulation. Enhancer of zeste homologue-2 (EZH2) is a histone methyltransferase, which catalyzes trimethylation of histone H3 at lysine 27 (H3K27me3) to control gene transcription critical for cell proliferation, function, differentiation and expansion. It controls the normal biology of germinal B cells. Epigenetic dysregulation is a hallmark of Diffuse large B- cell lymphoma (DLBCL) and follicular lymphoma (FL), with gain of function (GOF) EZH2 mutations. EZH2 is also overexpressed and plays an important role in lymphomagenesis. Follicular lymphoma (FL) pathogenesis includes epigenomic alterations affecting the immunological niche, and their potential consequences on the informational transfer between the microenvironment and tumor B cells. The introduction of novel target therapies and immunotherapeutics modalities in B cell lymphomas has shifted the treatment landscape. Tazemetostat received FDA approval as the first epigenetic therapy for FL. Valemetostat, which inhibits EZH1/2, as well as tazemetostat in combination with other drugs have been subject of recent research. The purpose of this article is to review the role of EZH2 in normal B cell differentiation and in the pathogenesis of B-Cell lymphomas.
PurposeThe integration of diagnostic tools, immunochemotherapy, targeted agents, and cellular therapies such as chimeric antigen receptor T-cell therapy (CAR-T) cells has transformed lymphoma outcomes in high-income countries. However, in Latin America (LATAM), access to these advances remains limited. This study aimed to assess lymphoma care access and institutional capacity in LATAM.MethodsWe conducted a cross-sectional digital survey from July 2025 to August 2025, coordinated by the Grupo de Estudio Latinoamericano de Linfoproliferativos network. The survey captured center-level data covering infrastructure, human resources, diagnostic and therapeutic availability, and clinical research activity. Data were analyzed using descriptive methods.ResultsA total of 73 hematology centers from 16 Latin American countries completed the survey. Most centers were public institutions (53%), with a median number of four hematologists per center (range, 2-10). While basic pathology and flow cytometry were widely available, access to advanced diagnostics was limited. Fifteen centers (21%) lacked immunohistochemistry, and pathology turnaround times exceeded 3 weeks in 56%. Positron emission tomography-computed tomography was available in 41% of centers. Novel therapies such as antibody-drug conjugates, bispecific antibodies, and checkpoint inhibitors were not available or restricted in most centers. Hematopoietic stem-cell transplantation was performed in 41% of centers, whereas commercial CAR-T was available in 5%. Clinical trials were conducted in 34% of centers.ConclusionOur findings highlight striking disparities between guideline-recommended lymphoma care and real-world institutional capacity across LATAM, underscoring the importance of collaborative efforts in building capacity and advocating for equitable access.